| Symbol | FDMT |
|---|---|
| Name | 4D MOLECULAR THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5858 HORTON STREET,SUITE 455, EMERYVILLE, California, 94608, United States |
| Telephone | +1 510 505-2680 |
| Fax | — |
| — | |
| Website | https://www.4dmoleculartherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001650648 |
| Description | 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Additional info from NASDAQ: |
📋 David Kirn (Officer) plans to sell 12K shares of 4D Molecular Therapeutics, Inc. (at $10.09 each, total $125K) Filed: Aug 03, 2026 | ID: 000473
Read more(99% Neutral) 4D MOLECULAR THERAPEUTICS, INC. (FDMT) Announces Clinical Development Update
Read more4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Read moreBizily Scott 🟡 adjusted position in 6.6K shares (2 derivative) of 4D Molecular Therapeutics, Inc. (FDMT) at $14.00 Transaction Date: Jun 30, 2026 | Filing ID: 000004
Read more4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
Read more(75% Positive) 4D MOLECULAR THERAPEUTICS, INC. (FDMT) Announces Business Combination
Read more4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
Read more4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
Read moreBizily Scott 🟡 adjusted position in 9.8K shares (1 derivative) of 4D Molecular Therapeutics, Inc. (FDMT) at $12.00 Transaction Date: Jun 23, 2026 | Filing ID: 000002
Read more